'For the quarter ending June 2023, consolidated Net sales (including other operating income) of Cipla has increased 17.74% to Rs 6328.89 crore compared to quarter ended June 2022. Sales of Phamaceuticals segment has gone up 15.48% to Rs 6,028.48 crore (accounting for 94.45% of total sales).  Sales of New Ventures segment has gone up 82.95% to Rs 354.45 crore (accounting for 5.55% of total sales).  Inter-segment sales rose Rs 38.94 crore to Rs 54.04 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 40.17% to Rs 1,390.99 crore.  PBIT of Phamaceuticals segment rose 36.81% to Rs 1,381.80 crore (accounting for 99.34% of total PBIT).  PBIT of New Ventures reported profit of Rs 9.19 crore compared to loss of Rs 17.62 crore.  

PBIT margin of Phamaceuticals segment rose from 19.35% to 22.92%.  PBIT margin of New Ventures segment rose from negative 9.09% to 2.59%. ...

• 

  (28-Feb-2026)

  Vesuvius India

  Net jumps 33% on higher OI
• 

  (26-Feb-2026)

  Foseco India

  Net down 35% on higher EO Exp
• 

  (26-Feb-2026)

  KSB

  Net up 11%, sales up 8%
• 

  (26-Feb-2026)

  Sanofi India

  OP down 23.67%